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Abstract
Background: WHO-defined pneumonias, treated with antibiotics, are responsible for a significant proportion of childhood
morbidity and mortality in the developing countries. Since substantial proportion pneumonias have a viral etiology, where
children are more likely to present with wheeze, there is a concern that currently antibiotics are being over-prescribed for it.
Hence the current trial was conducted with the objective to show the therapeutic equivalence of two treatments (placebo
and amoxycillin) for children presenting with non-severe pneumonia with wheeze, who have persistent fast breathing after
nebulisation with salbutamol, and have normal chest radiograph.
Methodology: This multi-centric, randomised placebo controlled double blind clinical trial intended to investigate
equivalent efficacy of placebo and amoxicillin and was conducted in ambulatory care settings in eight government hospitals
in India. Participants were children aged 2–59 months of age, who received either oral amoxycillin (31–54 mg/Kg/day, in
three divided doses for three days) or placebo, and standard bronchodilator therapy. Primary outcome was clinical failure on
or before day- 4.
Principal Findings: We randomized 836 cases in placebo and 835 in amoxycillin group. Clinical failures occurred in 201
(24.0%) on placebo and 166 (19.9%) on amoxycillin (risk difference 4.2% in favour of antibiotic, 95% CI: 0.2 to 8.1).
Adherence for both placebo and amoxycillin was .96% and 98.9% subjects were followed up on day- 4. Clinical failure was
associated with (i) placebo treatment (adjusted OR=1.28, 95% CI: 1.01 to1.62), (ii) excess respiratory rate of .10 breaths per
minute (adjusted OR=1.51, 95% CI: 1.19, 1.92), (iii) vomiting at enrolment (adjusted OR=1.49, 95% CI: 1.13, 1.96), (iv) history
of use of broncho-dilators (adjusted OR=1.71, 95% CI: 1.30, 2.24) and (v) non-adherence (adjusted OR=8.06, 95% CI: 4.36,
14.92).
Conclusions: Treating children with non-severe pneumonia and wheeze with a placebo is not equivalent to treatment with
oral amoxycillin.
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Introduction
Acute lower respiratory infections (ALRI) are a leading cause of
morbidity and mortality in children under five years of age in
developing countries and are responsible for an estimated 2.6
million deaths annually [1–3]. Wheezing and reactive airways
disease is associated with or contributory to a significant
proportion of childhood acute respiratory infections (ARI) [4–6].
The current Integrated Management of Childhood Illness (IMCI)
algorithm prescribes that children with wheeze and fast breathing
presenting to first level health facilities be given antibiotics if they
continue to have fast breathing after two doses of bronchodilators
[7]. However, an unknown proportion of children managed thus
will have viral related wheezing illness like bronchiolitis and
asthma rather than pneumonia, where antibiotics may not alter
the course of disease. Using IMCI algorithms are likely to result in
unnecessary administration of antibiotics as well as inadequate
treatment of wheeze [8].
Since our study hypothesis was that when given with an oral
bronchodilator, 3-days treatment with either oral amoxycillin or
PLoS ONE | www.plosone.org 1 April 2008 | Volume 3 | Issue 4 | e1991oral placebo would be as effective, in terms of clinical cure on day-
4, we designed a double blind equivalence trial. [9]. The goal of
this trial was to assess whether children of non-severe pneumonia
with wheeze can be effectively managed without antibiotics and to
identify which sub-group of cases do require antibiotics.
Methods
This was a multi-centric, double blind placebo-controlled
randomised trial conducted in outpatient departments of 8 referral
hospitals in India. Individual institutional ethics committees’ as
well as the IndiaClen Institutional Review Board approved the
study. It was designed for equivalence of two modes of therapy
with a predefined range of equivalence as an interval from 25% to
+5%. The trial was registered with the Clinical Trials registry
(NCT00407394). The protocol for this trial and supporing
CONSORT checklist are available as supporting information;
see Checklist S1 and Protocol S1.
Two-stage screening was done (verbal followed by standardised
screening) for inclusion and exclusion criteria. Children aged 2–59
months were verbally screened for complaints of cough, rapid
respiration, or difficulties in breathing. Excluded were those with
signs of WHO defined severe pneumonia or very severe disease[7],
other conditions requiring antibiotics therapy, clinically recog-
nized congenital heart disease, chronic systemic disorders,
hospitalisation in past 2 weeks, use of antibiotics in previous 2
days, measles within the last month, history of penicillin allergy
and prior enrolment in the study. Those who were verbal
screening positive and had no exclusion criteria were examined for
study entry criteria, which were audible or auscultatory wheeze
and WHO defined fast breathing, that is respiratory rate of $50
per minute (for age 2–11 months) or $40 per minute (for age 12–
59 months) [10]. Those who fulfilled the study entry criteria were
given a maximum of three doses of salbutamol (400 microgm/
dose) by either a nebuliser or metered dose inhaler and their
respiratory rate was reassessed. If fast breathing persisted above
WHO defined age specific cut-offs, a chest radiograph was taken
for diagnosing radiological pneumonia, defined as presence of
fluids, parenchymal infiltrates or consolidation [10]. Those with
radiological pneumonia were treated according to the standard
hospital treatment guidelines. The rest were invited to participate
in the study. Those who accepted the invitation were requested to
provide informed written parental consent in local language. Local
languages used were site specific and were Hindi for Lucknow,
Delhi and Chandigarh sites, Marathi for Nagpur and Mumbai
sites, Tamil for Chennai and Vellore site and Malayali for
Trivandrum site. Children of parents consenting for participation
were randomised to receive amoxycillin or placebo and continued
with oral salbutamol. Coordinating centre ensured standardised
training and quality assurance.
Follow up
All the participants were followed up on day- 4 and between
days 11–14 days. Home visits were done within 24 hours for those
who failed to report on the appointed days. Children who failed on
therapy, developed adverse reactions or withdrew consent were
treated according to standard hospital guidelines.
Intervention
Participants received either amoxycillin, 31–54 mg/Kg/day, in
three divided doses, or placebo, which looked and tasted similar to
amoxycillin, in three divided doses orally. In addition all participants
also received oral salbutamol, 2.5 ml or 5 ml thrice a day for ages 2–
11 months and 12–59 months, respectively (each 5 ml=2 mg
salbutamol). Patients with fever also received paracetemol (10–
15 mg/kg/dose) in addition to the study intervention.
Objectives
The primary objective was to compare the proportions of
eligible cases that achieve clinical cure on day- 4 on three-days of
treatment with either oral amoxycillin or placebo. Our secondary
objective was to compare the proportions that clinically relapsed
within the next 11–14 days, as well as identify the determinants, if
any, of clinical failure. Secondary laboratory outcome was the
proportions positive for respiratory syncycial virus (RSV) in
nasopharyngeal aspirate at enrolment.
Outcome measures
Main outcome measure was clinical cure on day- 4, defined as
those who were not assessed to have clinical failure. Clinical failure
was defined as either (i) development of WHO-defined severe
pneumonia or very severe disease (with or without wheeze) before
or on day- 4 assessment, or (ii) oxygen saturation on pulse
oximetry ,90% before or on day- 4 assessment or (iii) axillary
temperature .101 degrees F on day- 4 assessment, or (iv)
persistence of WHO-defined non-severe pneumonia on day- 4
assessment, or (v) presence of wheeze on day- 4 assessment. Loss to
follow up on day- 4 or withdrawal from the study at any time after
recruitment was also considered as therapy failure in the intention-
to-treatment (ITT) analysis. Clinical relapse was defined as cases,
which were clinically cured on day-4 assessment, but at days-11-14
follow-up showed signs of WHO-defined pneumonia.
Sample size
This was calculated for therapeutic equivalence of two
treatments (placebo and amoxycillin). It was assumed that the
overall failure rate would be 17% if the treatments were equivalent
[5]. We used d=0.05 to be the range of equivalence for the
difference in failure rates. To detect this difference using Type I
error probability (alpha) of 0.05 and power of 0.9, the required size
of each treatment group was 970.
Randomisation
A professional not associated with clinical care (GGA) generated
the randomization scheme at Lucknow. Randomised block sizes of
two to four were used to avoid any uneven distribution of patients
between two interventions. Unlabelled medicines were placed in
serially numbered opaque envelopes by the pharmacy. Doses were
provided for a maximum weight of 20 Kg. Extra doses were kept
for administration to a child who vomited within 30 minutes of
dosing. Health care workers, patients as well as research staff and
investigators were blinded.
Adherence
Adherence was assessed by pill count on day- 4 follow-up. Non-
adherence was defined as intake of less than 7 doses.
Laboratory procedures
A chest radiograph was taken prior to randomisation.
Nasopharyngeal aspirate was tested at enrolment for RSV using
Directogen
R kit (manufactured by Becton Dickinson and Compa-
ny, Sparks MD 21152, USA).
Statistical Analysis
Primary analyses were done on ITT basis. Per protocol analysis
was also done on subjects with complete follow-up and adherence
to treatment. We have used the two one-sided tests (TOST)
Pneumonia with Wheeze
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therapeutic equivalence of two treatments [11]. Baseline and other
characteristics were compared between the two regimens.
Association of clinical failure with different characteristics of
patients was assessed. Chi-squared test was used for testing two-
sided hypotheses, whereas Z- test was used to test one-sided
hypotheses. A p value of ,0.05 was considered to be statistically
significant. Crude odds ratios and 95% confidence intervals were
computed. The covariates, which were found to be significant or
nearly significant (p#0.10) in univariate analysis, were included to
construct a multivariate model for assessing determinants of
treatment failure by forward stepwise logistic regression. In the
later model, we also investigated the possibility of variables acting
as effect modifier for the risk factors. Final model included
covariates that were statistically significant. The primary outcome
measure was also assessed for each site and the overall odds ratio
after stratifying for site was obtained. Mantel-Haenszel statistic for
testing independence of clinical failure with interventions,
adjusting for site was used. Breslow-Day statistic for testing
three-factor interaction of clinical failure, interventions and site
was used. Data were analyzed using statistical software ‘‘Statistical
Package for Social Sciences’’ (SPSS) 11.0 version.
Results
Population
We nebulised 3487 children of non-severe pneumonia with
wheeze and in 46% (n=1604), the respiratory rate returned to
below age-specific cut-off (Figure 1). From among the remaining,
we recruited 1671 patients from February 2004 to July 2006
(Figure 1), 836 in the placebo and 835 in the amoxycillin group.
Loss to follow-up was 1% (n=8) and 1.2% (n=12) in the placebo
and amoxycillin groups by day-4, respectively and 3.6% (n=30)
and 4.6% (n=38), respectively by days-11-14.
Figure 1. CONSORT Statement for the trial.
doi:10.1371/journal.pone.0001991.g001
Pneumonia with Wheeze
PLoS ONE | www.plosone.org 3 April 2008 | Volume 3 | Issue 4 | e1991Baseline characteristics
There were no substantial differences in the baseline charac-
teristics of the treatment groups (Table 1).
Adherence to therapy
Adherence, defined as intake of 7 or more doses, for placebo
was 96.1% (791/823) and amoxycillin was 97.8% (801/819) with
the difference of 21.7% (95% CI: 23.3 to 20.03). In the placebo
and amoxycillin groups 88.1% (675/766) and 90.1% (686/761)
took 7 or more doses of oral bronchodilators (difference 22.0%;
95% CI: 25.1 to 1.1).
Primary and secondary Clinical Outcomes
On ITT analysis, the clinical failure rates were 24.0% (201/836)
and 19.9% (166/835) in the placebo and amoxycillin groups,
respectively, and the rate difference was 4.2% (95% CI: 0.2 to 8.2)
(Table 2). Comparing clinical failures in the two groups on per
protocol analysis gave very similar results. Here the confidence
interval for the risk difference (pA2pB) between the two treatments
covers at least some points which lie outside the equivalence range
(2d, +d). Note that d, the magnitude of difference of clinical
importance is taken to be 5.0% here. Now we used TOST
approach and tested one-sided hypothesis that the placebo is non-
inferior to amoxycillin, i.e. H0 :p A2pB$d (in-equivalence) vs H1:
pA2pB,d (equivalence). The corresponding test-statistic is
z=20.41 (p=0.34) (Table 2). We conclude, therefore, that the
hypothesis of ‘‘in-equivalence’’ cannot be disproved. The numbers
needed to treat (NNT) to avoid one clinical failure (or get one
additional cure) using amoxycillin is 24.
Among clinical failures on day- 4, 82.9% (160/193) in the
placebo group and 83.9% (131/156) in the amoxycillin group had
wheeze with or without any sign of hypoxia (oxygen saturation on
pulse-oximetry ,90%), severe pneumonia, very severe disease or
axillary temperature .101uF. Only those with associated wheeze
at the time of failure were at increased risk of having respiratory
rate above age specific cut-off in the placebo group (OR=6.0,
95% CI: 2.6–13.7; p value ,0.001) as well as in the amoxycillin
group (OR=4.4, 95% CI: 1.7–11.2; p value=0.001).
There was also no difference by group in the proportion of
clinical relapses, among those diagnosed as cure on day- 4
(Table 2).
Secondary laboratory Outcome
RSV antigen was positive in 5.6% (88/1558) at enrolment
(Table 1).
Risk factors associated with clinical failure
Significant univariate association of clinical failure were found
with current history of fever and use of liquid petroleum gas for
cooking at home (Table 3), but these were not significant in the
multiple regressions. Variables which had significant association in
both univariate and the multiple logistic regression model with
clinical failure were current history of vomiting, past history of use
of bronchodilator, excess respiratory rate of .10 breaths per
minute above age specific cut-off and non-adherence (Table 4); the
adjusted odds ratio for clinical failure with the use of placebo was
1.28 (95% CI: 1.01 to1.62; p value=0.04).
Adverse reactions
These had similar frequencies in both arms. There were no
deaths and 30 hospitalisations (15 in each group). There were 11
cases of nausea and mild vomiting, 2 cases of diarrhoea with some
dehydration, 9 cases of diarrhoea with no dehydration, 1 rash
without itch, and 1 case of tremors.
Discussion
This was a randomised, double blind placebo controlled trial to
assess whether children of non-severe pneumonia with wheeze can
be effectively managed without antibiotics. We have found that
clinical failure was associated with placebo treatment (adjusted
OR=1.28, 95% CI: 1.01 to1.62). Other variables associated with
clinical failure on multivariable analysis were history of vomiting,
Table 1. Comparison of Baseline characteristics of patients’
pneumonia by treatment type.
CONTINUOUS VARIABLES Placebo Amoxycillin
(n=836) (n=835)
Mean, SD Mean, SD
Age (months) 19.5, 14.3 20.0, 14.6
Weight (Kg) 9.1, 2.5 9.2, 2.7
Height (Cm) 76.4, 12.1 76.6, 12.4
Duration of illness (days) 3.9, 1.8 3.8, 1.8
Temperature (uFahrenheit) 98.9, 0.9 98.9, 0.9
Respiratory Rate (breaths/minute) 52.6, 7.3 52.5, 7.5
Heart Rate (per minute) 115.8, 16.5 115.5, 16.4
CATEGORICAL VARIABLES Placebo Amoxycillin
(n, % n, %
Female 301, 35.9 300, 35.9
Age 2–11months 334, 39.8 322, 38.6
Weight for height,23 SD 33, 3.9 33, 4.0
History of Current Illness
Duration of illness.=3days 651, 77.6 637, 76.3
Fever 468, 55.8 470, 56.3
Vomiting 183, 21.8 164, 19.6
Diarrhoea 8, 1.0 5, 0.6
History of Allergic disorders in subject
Asthma 109, 13.0 107, 12.8
Allergic rhinitis 55, 6.6 54, 6.5
Eczema 6, 0.7 4, 0.5
Urticarial rash 7, 0.8 4, 0.5
Use of Bronchodilator 184, 21.9 183, 21.9
History of exposure Pollutants
Smoker in family 245, 29.2 271, 32.5
Biomass fuel use for cooking 349, 41.6 348, 41.7
LPG use for cooking 531, 63.3 520, 62.3
Examination
Respiratory Rate.10 breaths per minute
above cut-off
333, 39.7 340, 40.7
Wheeze (On Auscultation) 704, 83.9 720, 86.2
Wheeze (Audible) 135, 16.1 115, 13.8
RSV positive
1 48/778, 6.2 40/780, 5.1
1For these variables, the results are presented in fractions, as the denominators
are different.
Abbreviations:
SD: Standard deviation, RSV: Respiratory syncitial virus, LPG: Liquid Petroleum
Gas
doi:10.1371/journal.pone.0001991.t001
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PRIMARY OUTCOME: FAILURE RATE Placebo Amoxycillin Difference, p value
m/n, % m/n, % 95% C.I.
Intention to Treat Analysis 201/836, 24.1 166/835, 19.9 4.2 (0.2, 8.2) 0.34
Per Protocol Analysis 172/791, 21.7 140/801, 17.5 4.3 (0.3, 8.1) 0.36
SECONDARY OUTCOME: RELAPSE RATE
Among those cured on day- 4 44/635, 6.9 41/669, 6.1 0.8 (21.9, 3.5) p=0.6
Abbreviations:
m/n: numerator/denominator
CI: Confidence Interval
doi:10.1371/journal.pone.0001991.t002
Table 3. Association of clinical failure with different characteristics of patients (univariate Intention to Treat Analysis).
Variables Clinical failure Clinical Cure Adjusted
2 p-value
(N=367) (N=1304) odds ratio, 95% C.I.
number, % number, %
Female 127, 34.6 473,36.3 0.9(0.7,1.2) 0.6
Age 2–11months 157,42.8 497,38.1 1.2(1.0,1.5) 0.11
Malnutrition* 9, 2.5 57, 4.4 0.6(0.3,1.1) 0.10
History of Current Illness
Duration of illness .=3days 293, 79.8 992,76.1 1.2(0.9,1.7) 0.14
Fever 230, 62.7 707, 54.2 1.4(1.1,1.8) 0.004
Vomiting 102, 27.8 244, 18.7 1.7(1.3,2.2) ,0.001
Cough 366,99.7 1297,99.5 2.0(0.2,16.1) 0.5
Diarrhea 3, 0.8 10, 0.8 1.0(0.3,3.8) 0.96
Difficult breathing 0 2, 0.2 0.5
History of Allergic disorders
Asthma 45, 12.3 171, 13. 0.9(0.7, 1.3) 0.7
Allergic rhinitis 18, 4.9 91, 7.0 0.7(0.4, 1.2) 0.2
Eczema 2, 0.5 8, 0.6 0.9(0.2, 4.1) 0.9
Urticarial rash 0 11, 0.8 0.08
Use of Bronchodilator 107, 29.2 259, 19.9 1.7(1.3, 2.2) ,0.001
History of exposure Pollutants
Smoker in family 127, 34.6 388, 29.8 1.3(1.0, 1.6) 0.06
Biomass fuel use for cooking 162, 44.1 534, 41.0 1.1(0.9, 1.4) 0.3
LPG use for cooking 211, 57.5 837, 64.2 0.8(0.6, 1.0) 0.02
Examination
Respiratory Rate .10 units of cut-off 172, 46.9 500, 38.3 1.4(1.1, 1.8) 0.003
Wheeze (On Auscultation) 320, 87.2 1101, 84.4 1.3(0.9, 1.8) 0.2
RSV positive
1 16/349, 4.6 72/1206, 6.0 0.7(0.4, 1.3) 0.3
Non-Adherence
1 34/346, 9.8 16/1296, 1.2 8.5(4.6,15.6) ,0.001
*Weight-for-height,23SD
1For these variables, the results are expressed in fractions as their denominators are different.
2Adjusted for intervention effect.
Abbreviations:
LPG: Liquid Petroleum Gas
RSV: Respiratory Syncitial Virus
CI: Confidence Interval
doi:10.1371/journal.pone.0001991.t003
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per minute above age specific cut off and non-adherence (Table 4).
Therefore, there is no need for modification of the current WHO
guidelines for the treatment of pneumonia [10].
This study was designed as an equivalence trial [9,11] to get as
close to the truth as possible with unbiased results. Our pre-
specified value of 5% defined the smallest difference (excess) in
clinical failure rates with the use of placebo that would be of
clinical interest. In the ITT as well as per protocol analysis, the
estimated difference in clinical failure was ,5% but the confidence
interval covered points that lie outside the equivalence range
(upper confidence limit is greater than +d). So the differences of
potential clinical importance remain a real possibility and
equivalence cannot be safely concluded on the basis of
‘‘confidence interval’’ approach. We used the other commonly
used statistical approach of TOST to avoid any ambiguity in
assessing the therapeutic equivalence. The TOST approach
suggests that the hypothesis of in-equivalence cannot be disproved,
which would then favour the use of antibiotics. The study was
originally planned to have a power of 90%, but with the estimated
overall failure rate of 22% and average sample of size of 835.5, the
power of current study is 79.5%. It is recommended that a further
study should be planned with a greater power using the estimates
of failure rate of the current study.
Clinical failure as defined in this study was a composite
measure. Since presence of hypoxia, severe pneumonia and very
severe disease were responsible for similar proportions of clinical
failures in both the treatment groups, and since .80% of clinically
failed had wheeze along with respiratory rate above the age
specific cut-off, failure was possibly due to inadequate broncho-
dilator therapy. However, theoretically clinical failure due to
inadequate antimicrobial therapy cannot also be ruled out. We
used amoxycillin that is affective against most strains of Haemophilus
influenzae and Streptococcus pneumoniae, which are major causes of
bacterial pneumonia [12]. Since clinical failures for reasons other
than fast breathings were similar in the placebo as well as
antibiotic groups, it is unlikely that these subjects would have
benefited with antibiotics. On the contrary, they possibly require
intensive bronchodilator therapy as recommended in the guide-
lines for management of cases of asthma without hypoxia [13].
Previous trials of antibiotics for treatment of non- severe
pneumonia have documented respiratory rate .10 breath per
minute above age specific cut off as a predictor of clinical failure
[5,6], as reported in the current study. A study from Pakistan
reported temperature .100uF at baseline in wheezers with
pneumonia as predictive of subsequent deterioration [14] as seen
by us in univariate analysis. We have not found this relationship in
multivariate analysis. Therefore, fever at baseline cannot be taken
as an absolute criterion for giving antibiotics. In our study 4.9% of
children with clinical failure had fever above 101uF, which could
be either due to bacterial or viral etiology. Those with bacterial
etiology of fever could be benefited with antibiotic therapy.
Wheezing is commonly associated with viral infections,
particularly due to RSV [15]. However, the sample size of RSV
positive cases in this study was too small to provide a precise
estimate of the association in this particular sub-group. The
proportion of RSV positivity was similar to a previous study
conducted in same sites, and was low [5]. Lack of association
between clinical failure and RSV could be due to the small
number of RSV positive patients in the current study.
In our study past history of asthma and/or use of bronchodi-
lators was not an exclusion criteria. This was done because in
young children there are multiple causes of wheezing and asthma
is just one of them. Thus, we have increased the generalizability of
our results. We have found that, controlling for the use of
antibiotic in logistic regression model, children with past history of
use of bronchodilators are at increased risk of clinical failure,
which is most likely due to inadequate bronchodilator therapy. In
this sub-group of children further study is needed to define the
benefit of concomitant antibiotic therapy when they get fast
breathing, in the range of WHO-defined non-severe pneumonia.
We have found that among cases of non-severe pneumonia and
wheeze, the respiratory came back below age specific cut-offs in
46% (1605/3487) children and thus there was no need to prescribe
antibiotic. Similar findings have been reported from Pakistan [15].
The IMCI guideline also recommends use of bronchodilators
among wheezers before deciding to treat them as cases of
pneumonia with antibiotics. Implementation of IMCI guidelines
in ambulatory care settings in India as well as other developing
countries with result in a substantial reduction in prescription of
antibiotics for non-severe pneumonia.
From this study we have found that treating 24 cases of non-
severe pneumonia with wheeze with 3-days of oral amoxycillin
along with bronchodilators will avert 1 clinical failure. With these
NNT, in the developed countries treating non-severe pneumonia
with wheeze without antibiotics may be considered since
vaccination against Haemophilus influenzae and Streptococcus pneumo-
niae, are a part of their Expanded Program of Immunization (EPI).
However, these vaccines are not a part of the EPI program in most
developed countries, hence we have to continue to treat such
Table 4. Multivariable logistic regression model for the factors associated with Clinical failure on Intention to Treat Analysis.
Variables Crude Odds Ratio (95% C.I.) Adjusted odds ratio (95% CI) p value of adjusted odds’ ratio
Intervention with Placebo 1.3 (1.03, 1.66) 1.28 (1.01, 1.62) 0.04
History of Current Illness
Vomiting 1.7 (1.3,2.2) 1.50 (1.14, 1.98) 0.004
History of Allergic disorders
Use of Bronchodilator 1.7(1.3, 2.2) 1.72 (1.31, 2.26) ,0.001
Clinical Examination
Respiratory Rate.10 breaths per minute
above cut-off
1.4 (1.1, 1.8) 1.51 (1.18, 1.92) 0.001
Non-adherence 9.0 (4.9, 16.4) 8.24 (4.46, 15.20) ,0.001
Abbreviation:
CI: Confidence Interval
doi:10.1371/journal.pone.0001991.t004
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failures as a result of bacterial pneumonia. For a 12.5 Kg child,
oral amoxycillin will cost just 0.3 USD [16] and thus in 7.2 USD
one failure can be averted. Given the incidence rate of 536 non-
severe acute lower respiratory infections/1000 child years from
India [17] of which about 13% will have also wheeze [5] this
translates into an annual cost of USD 315,0000 on oral
amoxycillin in India with about 1 billion population of which
15% are below 5 years of age. This cost cannot be averted for now
as we found that treatment with placebo is not equivalent to that of
3-days of oral amoxycillin in such cases.
The strength of the study was that it was a multi-centric, double
blind, placebo controlled trial, with good adherence and minimal
follow-up in spite of ambulatory study design. Since we were using
placebo to treat children of non-severe pneumonia, where
antibiotics have been recommended by the WHO [10], we had
to exclude those with radiological pneumonia from the trial to
avoid exposing them to risky placebo treatment arm. While this
has maximized the principle of avoiding harm to the patients from
ethical as well as good clinical practises point of view, it has also
reduced the generalizability of our findings. Since we have
concluded that treatment with placebo and amoxycillin is not
equivalent we have actually benefited children with radiological
pneumonia by treating them with standard guidelines that does
include antibiotics. Baseline and outcome variables were homo-
geneous across the sites. Since there was misinterpretation of
radiological pneumonia, there were 3 cases of protocol deviations.
We also did not investigate for microbial profile, as this is not done
in routine community practise.
To conclude, treating children with non-severe pneumonia and
wheeze with a placebo is not equivalent to treatment with oral
amoxycillin since even though the estimated difference in clinical
failure was ,5% but the confidence interval covers points, which
lie outside the equivalence range (upper confidence limit is greater
than +5%). Perhaps more aggressive bronchodilator therapy will
also benefit such patients, especially those with history of prior use
of bronchodilators. Patients with respiratory rate .10 breaths per
minute above cut-off should be studied further for the benefits of
antibiotic therapy.
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